Robert R Langley1, Isaiah J Fidler. 1. Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: It is estimated that at least 200 000 cases of brain metastases occur each year in the US, which is 10 times the number of patients diagnosed with primary brain tumors. Brain metastasis is associated with poor prognosis, neurological deterioration, diminished quality of life, and extremely short survival. Favorable interactions between tumor cells and cerebral microvascular endothelial cells encourage tumor growth in the central nervous system, while tumor cell interactions with astrocytes protect brain metastases from the cytotoxic effects of chemotherapy. CONTENT: We review the pathogenesis of brain metastasis and emphasize the contributions of microvascular endothelial cells and astrocytes to disease progression and therapeutic resistance. Animal models used to study brain metastasis are also discussed. SUMMARY: Brain metastasis has many unmet clinical needs. There are few clinically relevant tumor models and no targeted therapies specific for brain metastases, and the mean survival for untreated patients is 5 weeks. Improved clinical outcomes are dependent on an enhanced understanding of the metastasis-initiating population of cells and the identification of microenvironmental factors that encourage disease progression in the central nervous system.
BACKGROUND: It is estimated that at least 200 000 cases of brain metastases occur each year in the US, which is 10 times the number of patients diagnosed with primary brain tumors. Brain metastasis is associated with poor prognosis, neurological deterioration, diminished quality of life, and extremely short survival. Favorable interactions between tumor cells and cerebral microvascular endothelial cells encourage tumor growth in the central nervous system, while tumor cell interactions with astrocytes protect brain metastases from the cytotoxic effects of chemotherapy. CONTENT: We review the pathogenesis of brain metastasis and emphasize the contributions of microvascular endothelial cells and astrocytes to disease progression and therapeutic resistance. Animal models used to study brain metastasis are also discussed. SUMMARY:Brain metastasis has many unmet clinical needs. There are few clinically relevant tumor models and no targeted therapies specific for brain metastases, and the mean survival for untreated patients is 5 weeks. Improved clinical outcomes are dependent on an enhanced understanding of the metastasis-initiating population of cells and the identification of microenvironmental factors that encourage disease progression in the central nervous system.
Authors: Dmitry A Nedosekin; Mazen A Juratli; Mustafa Sarimollaoglu; Christopher L Moore; Nancy J Rusch; Mark S Smeltzer; Vladimir P Zharov; Ekaterina I Galanzha Journal: J Biophotonics Date: 2013-05-16 Impact factor: 3.207
Authors: Bisrat G Debeb; Lara Lacerda; Simone Anfossi; Parmeswaran Diagaradjane; Khoi Chu; Arvind Bambhroliya; Lei Huo; Caimiao Wei; Richard A Larson; Adam R Wolfe; Wei Xu; Daniel L Smith; Li Li; Cristina Ivan; Pamela K Allen; Wenhui Wu; George A Calin; Savitri Krishnamurthy; Xiang H Zhang; Thomas A Buchholz; Naoto T Ueno; James M Reuben; Wendy A Woodward Journal: J Natl Cancer Inst Date: 2016-04-13 Impact factor: 13.506
Authors: Filipa D Oliveira; Marco Cavaco; Tiago N Figueira; Javier Valle; Vera Neves; David Andreu; Diana Gaspar; Miguel A R B Castanho Journal: FEBS J Date: 2021-11-07 Impact factor: 5.622